Bibliographic Details
| Title: |
Reactogenicity Differences between Adjuvanted, Protein-Based and Messenger Ribonucleic Acid (mRNA)-Based COVID-19 Vaccines |
| Authors: |
Matthew D. Rousculp, Kelly Hollis, Ryan Ziemiecki, Dawn Odom, Anthony M. Marchese, Mitra Montazeri, Shardul Odak, Laurin Jackson, Hadi Beyhaghi, Seth Toback |
| Source: |
Vaccines, Vol 12, Iss 7, p 802 (2024) |
| Publisher Information: |
MDPI AG, 2024. |
| Publication Year: |
2024 |
| Collection: |
LCC:Medicine |
| Subject Terms: |
booster, COVID-19, reactogenicity, real-world evidence, SARS-CoV-2, NVX-CoV2373, Medicine |
| More Details: |
Participants in studies investigating COVID-19 vaccines commonly report reactogenicity events, and concerns about side effects may lead to a reluctance to receive updated COVID-19 vaccinations. A real-world, post hoc analysis, observational 2019nCoV-406 study was conducted to examine reactogenicity within the first 2 days after vaccination with either a protein-based vaccine (NVX-CoV2373) or an mRNA vaccine (BNT162b2 or mRNA-1273) in individuals who previously completed a primary series. Propensity score adjustments were conducted to address potential confounding. The analysis included 1130 participants who received a booster dose of NVX-CoV2373 (n = 303) or an mRNA vaccine (n = 827) during the study period. Within the first 2 days after vaccination, solicited systemic reactogenicity events (adjusted) were reported in 60.5% of participants who received NVX-CoV2373 compared with 84.3% of participants who received an mRNA vaccine; moreover, 33.9% and 61.4%, respectively, reported ≥3 systemic reactogenicity symptoms. The adjusted mean (95% CI) number of systemic symptoms was 1.8 (1.6–2.0) and 3.2 (3.0–3.4), respectively. Local reactogenicity events (adjusted) were reported in 73.4% and 91.7% of participants who received NVX-CoV2373 and mRNA vaccines, respectively; the adjusted mean (95% CI) number of local symptoms was 1.5 (1.33–1.61) and 2.4 (2.31–2.52), respectively. These results support the use of adjuvanted, protein-based NVX-CoV2373 as an immunization option with lower reactogenicity than mRNAs. |
| Document Type: |
article |
| File Description: |
electronic resource |
| Language: |
English |
| ISSN: |
2076-393X |
| Relation: |
https://www.mdpi.com/2076-393X/12/7/802; https://doaj.org/toc/2076-393X |
| DOI: |
10.3390/vaccines12070802 |
| Access URL: |
https://doaj.org/article/4a6215e46a214139a474118ea9ab0af3 |
| Accession Number: |
edsdoj.4a6215e46a214139a474118ea9ab0af3 |
| Database: |
Directory of Open Access Journals |
